A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

​ Conditions: NK/T Cell Lymphoma

Interventions: Drug: DAPT regimen plus radiotherapy

Sponsors: Peking University Cancer Hospital & Institute; Peking University International Hospital; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Recruiting Conditions: NK/T Cell Lymphoma
Interventions: Drug: DAPT regimen plus radiotherapy
Sponsors: Peking University Cancer Hospital & Institute; Peking University International Hospital; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Recruiting